Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

IMAX Corporation (USA) (IMAX): Can RealD (RLD) Bounce Back?

Shares of RealD (NYSE:RLD) are bucking the rising equity markets, losing 16% of their value last week.

A poor report on box office receipts for August pressured the outfitter of movie theaters into venues for 3-D screenings.

RealD (NYSE:RLD) reported on Wednesday that RealD-enabled screens took in roughly $165 million in ticket sales for the month of August. The box office tally consisted of $66 million in domestic sales and $99 million internationally.

RealD (NYSE:RLD)The disappointing showing was essentially flat with RealD (NYSE:RLD)’s performance a year earlier. The company was working on a different fiscal calendar last year, but movie theaters sold $167 million in admissions during the four weeks ending on August 17. Domestic ticket sales were up nicely, but naturally that means that international receipts fell by an even larger amount.

If we go all the way back to the beginning of the fiscal quarters, we’re looking at $551 million in box office returns from RealD-enabled screens during the first eight weeks of last summer’s fiscal second quarter. It was just $502 million over the slightly longer period covering July and August this year.

The decline is more prominent in that span of time, and that includes dips both here and abroad for RealD (NYSE:RLD) screens.

This should be a good time to be running a premium platform for enjoying movies. The economy’s showing signs of life. AMC Theaters is about to go public. And at least one major player in this niche is holding up just fine.

IMAX Corporation (USA) (NYSE:IMAX) actually hit a new two-year high last week.

Then again, it’s probably not fair to compare RealD and IMAX Corporation (USA) (NYSE:IMAX) anymore. RealD (NYSE:RLD)’s most recent quarter was called “challenging” by the company as revenue slid 13%.

“Moviegoers were more selective than expected regarding the films they chose to experience in 3-D,” RealD explained at the time. In other words, jaded audiences just aren’t open to shelling out a few extra bucks to see a theatrical release with 3-D effects.

IMAX Corporation (USA) (NYSE:IMAX) hasn’t suffered that way. A super-sized IMAX screening remains a social event, and revenue climbed 17% in its latest quarter. Adjusted net income also grew even faster at IMAX Corporation (USA) (NYSE:IMAX), and that’s a stark contrast to the four consecutive quarterly deficits that RealD has cranked out.

These are challenging times for RealD (NYSE:RLD), as analysts see losses widening and revenue sliding through this fiscal year that ends next March. Has it just been the past year of movies that haven’t been compelling enough to catch in 3-D or are customers shedding 3-D at the corner multiplex the same way they dissed 3-D televisions at consumer electronics stores over the past couple of years?

RealD will have to prove that audiences still crave 3-D without flinching for a premium before the company can truly bounce back. Moviegoers don’t mind paying more if they value the experience. IMAX Corporation (USA) (NYSE:IMAX) is living proof of that, and with an installation backlog of more than 280 screens, it’s safe to say that exhibitors feel the same way about IMAX Corporation (USA) (NYSE:IMAX).

RealD needs to fade to black — instead of fading in popularity — for the stock to claw its way out of the single digits.

The article Can RealD Bounce Back? originally appeared on and is written by Rick Munarriz.

Longtime Fool contributor Rick Munarriz has no position in any stocks mentioned. The Motley Fool recommends and owns shares of IMAX.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!